Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

Overview of attention for article published in Frontiers in Pharmacology, October 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy

Article in Antibodies (May 2024)

Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient

Article in Acta Pharmacologica Sinica (February 2024)

Anaplastic Lymphoma Kinase (ALK) in Posterior Cranial Fossa Tumors: A Scoping Review of Diagnostic, Prognostic, and Therapeutic Perspectives

Article in Cancers (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.